AbbVie Inc. (NYSE:ABBV) on Monday revealed topline results from the Phase 3 AFFIRM study evaluating the efficacy of risankizumab in treating Crohn’s disease. This news comes as broader markets are experiencing a mixed day, with the Dow Jones down 0.38% and the S&P 500 declining 0.31%.

Crohn’s disease is a chronic, systemic disease that manifests as inflammation within the gastrointestinal tract, most commonly in the area between the small intestine (ileum) and the colon, causing persistent diarrhea and abdominal pain.

The company’s AFFIRM study showed that 55% of patients treated with risankizumab achieved clinical remission at week 12, compared to 30% in the placebo group.

Additionally, 44% of patients experienced an endoscopic response, significantly higher than the 14% in the placebo group, reinforcing risankizumab’s potential as a leading treatment option for Crohn’s disease.

The study included a predominantly treatment-refractory population, with 65% of participants having failed two or more advanced therapies. These findings highlight the effectiveness of risankizumab in a challenging patient demographic, indicating AbbVie’s ongoing commitment to innovation in immunology.

Competitive Landscape

William Blair on Monday noted, “The positive results are strategically important for Skyrizi's competitive ...